Center for Immunotherapy and Cell-Based Technologies

Novosibirsk — Kaliningrad — Moscow — Irkutsk
Main

Melanoma

Xenovaccinotherapy for cancer

http://www.medicalnewstoday.com/rss/cancer-oncology.xmlhttp://www.medicalnewstoday.com/rss/immune_system.xmlhttp://www.medicalnewstoday.com/rss/multiple_sclerosis.xmlhttp://www.medicalnewstoday.com/rss/stem_cell_research.xml

29.07.2019 Scientists find that fat cells transfer gene-altering proteins to melanoma cells, making them more aggressive. They also show a way to block this proc...

02.04.2019 An international study has identified gut bacteria that activate the immune system to slow melanoma growth in mice and highlights a key signaling path...

16.03.2019 A Ph.D. student has designed a cost-effective and easy-to-use device that can quickly detect cancerous skin cells. Catching cancer earlier can save li...

14.03.2019 Melanoma is notoriously difficult to treat. Recently, scientists have looked to marine bacteria to find novel ways of attacking this type of skin canc...

01.03.2019 New research examines the genetic chain reaction that causes a particularly aggressive form of melanoma and finds a way to stop it....

26.01.2019 New research finds that therapy with a genetically modified herpes virus is highly effective in the treatment of stage 3 melanoma, with few side effec...

24.01.2019 A recent study examines melanoma mortality across the United States. The researchers identify large differences between states. Why could this be?...

21.11.2018 Recent research suggests that stopping the proteins LRP1 and tPA from interacting could form the basis of a treatment to halt metastasis in melanoma....

06.11.2018 Nodular melanoma is the most aggressive form of skin cancer. In this article, we look at the symptoms, causes, risk factors, and treatments for nodula...

29.10.2018 Skin cancer is the most common cancer in the United States. People should check every month for signs of melanoma and other skin cancers. In this arti...


Immunotherapy for cancer

An active specific immunotherapy (vaccinotherapy) is a strategy using tumor-associated antigens for including antitumor immune responses. The small structural distinctions of the xenogenic tumor-associated antigens from their human analogues render these antigens highly immunogenic and capable of including immune-mediated, antitumor responses in a patient not only at early, but also at advanced stages of disease, when tumor-derived immunosuppression is significant. Tumor-specfic immunotherapy is able to generate a selective and long-term antitumor effect. Such a therapy has no complications attributable to chemotherapy.

Xenovaccinotherapy for cancer